Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815359 · ClinicalTrials.gov registry record · Phase 2
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
A Phase 2 study of Colorectal Cancer and Appendix Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 292
- Enrollment target
- 9
- Study locations
NCT01815359: Active Phase 2 study of Colorectal Cancer and Appendix Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01815359 is a Phase 2 study of Colorectal Cancer and Appendix Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 292 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (81% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01815359, a Phase 2 study of Colorectal Cancer and Appendix Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 292 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.
Conditions Studied
Interventions
- PROCEDURE Cytoreductive Surgery
- DRUG HIPEC with Mitomycin-C
- DRUG EPIC with FUDR and Leucovorin
Study Locations (9)
New York
- Memorial Sloan Kettering Commack (Consent and Follow up) - Commack
- Memorial Sloan Kettering Westchester (Consent and Follow up) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent and Follow up) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent and Follow up) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent and Follow up) - Middletown
- Memorial Sloan Kettering Bergen (Consent and Follow up) - Montvale
Florida
- University of Miami - Miami
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2013-03 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01815359
The ClinicalTrials.gov registry entry for NCT01815359 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cytoreductive Surgery is the first listed.
NCT01815359 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT01815359 about?
NCT01815359 is a clinical study titled "ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis". This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductiv...
What is the current status of trial NCT01815359?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 292 participants. The study started on 2013-03. Estimated completion is 2026-09.
What conditions does trial NCT01815359 study?
This clinical trial studies the following conditions: Colorectal Cancer, Appendix Cancer.
What interventions are being tested in trial NCT01815359?
The interventions under investigation include: Cytoreductive Surgery (PROCEDURE), HIPEC with Mitomycin-C (DRUG), EPIC with FUDR and Leucovorin (DRUG).
Who is sponsoring clinical trial NCT01815359?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01815359 being conducted?
This trial has 9 study locations across Florida, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.